Stay updated with breaking news from Key Recent Program Updates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation...
AVEO Oncology Highlights Recent Progress and 2022 Outlook - read this article along with other careers information, tips and advice on BioSpace
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted...